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Abstract
Background: Non-tubercular mycobacteria (NTM) has not been given due attention till the
recent epidemic of HIV. This has led to increasing interest of health care workers in their biology,
epidemiology and drug resistance. However, timely detection and drug susceptibility profiling of
NTM isolates are always difficult in resource poor settings like India. Furthermore, no standardized
methodology or guidelines are available to reproduce the results with clinical concordance.
Objective: To find an alternative and rapid method for performing the drug susceptibility assay in
a resource limited settings like India, we intended to evaluate the utility of Tetrazolium microplate
assay (TEMA) in comparison with proportion method for reporting the drug resistance in clinical
isolates of NTM.
Methods: A total of fifty-five NTM isolates were tested for susceptibility against Streptomycin,
Rifampicin, Ethambutol, Ciprofloxacin, Ofloxacin, Azithromycin, and Clarithromycin by TEMA and
the results were compared with agar proportion method (APM).
Results: Of the 55 isolates, 23 (41.8%) were sensitive to all the drugs and the remaining 32 (58.2%)
were resistant to at least one drug. TEMA had very good concordance with APM except with
minor discrepancies. Susceptibility results were obtained in the median of 5 to 9 days by TEMA.
The NTM isolates were highly sensitive against Ofloxacin (98.18% sensitive) and Ciprofloxacin
(90.09% sensitive). M. mucogenicum was sensitive only to Clarithromycin and resistant to all the
other drugs tested. The concordance between TEMA and APM ranged between 96.4 – 100%.
Conclusion: Tetrazolium Microplate Assay is a rapid and highly reproducible method. However,
it must be performed only in tertiary level Mycobacteriology laboratories with proper bio-safety
conditions.
Background
The number and species of Non-tubercular mycobacteria
(NTM) isolated from clinical specimens is continuously
increasing with the advancement of microbiological
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detection methods. Numbers of reports have confirmed
the pathogenic role, morbidity and mortality caused by
NTMs in AIDS patients [1-4]. The infection due to NTM is
difficult to treat because of their intrinsic resistance to the
major classes of drugs, probably due to their habitat [5,6].
Therefore to choose an effective therapeutic drug, anti
mycobacterial susceptibility testing becomes a primary
step for the management of the NTM disease. Though
there are specific recommendations and guidelines pre-
scribed by the World Health Organization (WHO) and
Centre for Disease Control (CDC) regarding anti-tubercu-
lar drug susceptibility methods for Mycobacterium tubercu-
losis there are no such guidelines for NTMs. As routine
drug susceptibility testing of NTMs are discouraged, there
are circumstances where susceptibility testing is warranted
[7].
Traditionally drug susceptibility testing in mycobacterial
isolates is performed in agar and Lowenstein Jensen (LJ)
medium which is considered as a 'gold standard' but it is
cumbersome and available only in few reference laborato-
ries in a country like India where tuberculosis is highly
endemic. Even though automated systems dramatically
reduced the time for detecting drug resistance in mycobac-
terial isolates but these are more expensive and not feasi-
ble especially in a low resource setting [8-12].
Since there was a need for rapid, easy to perform and qual-
itative method for predicting the Minimal Inhibitory Con-
centration (MICs) for NTM isolates, Mshana et al [13]
developed a rapid colorimetric method employing oxida-
tion-reduction indicator Tetrazolium bromide to perform
drug susceptibility testing for Mycobacterium tuberculosis
which was found to be promising and cost effective [14].
Therefore, we intended to assess the performance and effi-
ciency of Tetrazolium Microplate Assay (TEMA) for deter-
mining MICs of Streptomycin (STR), Rifampicin (RIF),
Ethambutol (ETH), Ciprofloxacin (CIP), Ofloxacin
(OFL), Azithromycin (ATH) and Clarithromycin (CLA)
against clinically isolated NTMs. The results obtained by
TEMA were compared with Agar Proportion Method
(APM) on Middle brook 7H10 agar plates.
Methods
Mycobacterial isolates
A total of fifty-five NTMs isolated from patients referred to
our laboratory for mycobacterial isolation were included,
as shown in Table 1. These strains were identified and
confirmed as NTM by biochemical methods such as heat
stable catalase, niacin and nitrate production, aryl sul-
phatase and sodium chloride tolerance test [15] and DNA
sequencing was done with targets of 16S rRNA and 16S-
23S Internal Transcribed Spacer sequences or hsp65 as pre-
viously reported elsewhere [16]. Standard strains [M.
avium (NCTC-8551), M. chelonae (TMC-1544), M. xenopi
(NCTC-10042), M. phlei (NCTC-8156), M. intracellularae
(TMC1406),  M. simiae (TMC 1226), M. fortuitum
(TMC1529), M. smegmatis (TMC1546), M. terrae (TMC-
1450) & M. kansasii] used as controls against the clinical
N T M  i s o l a t e s  w e r e  k i n d l y  g i f t e d  b y  D r .  V .  M .  K a t o c h ,
National JALMA Institute of Leprosy and Other Mycobac-
terial Diseases, Agra, India.
Inoculum and drug preparation
Antimycobacterial drugs were procured from commercial
source (Sigma®, U.S.A) and solubilised according to the
manufacturer's recommendations in appropriate solvents
and sterilized by filtering through 0.22 μm membrane fil-
Table 1: Mean MICs of drugs (μg/mL) against clinical isolates of Non-tubercular mycobacterial isolates
Clinical isolate (n) STR RIF ETH CIP OFL ATH CLA
M SD M SD M SD M SD M SD M SD M SD
M. avium (16) 0.6 1.69 0.5 0.96 57.7 66.63 0.27 0.48 0.6 0.16 158.5 215.9 22.2 32.53
M. abscess (1) 0.22 - 0.22 - 138.3 - 0.13 - 0.66 - 1.37 - 0.16 -
M. chelonae (7) 3.98 10.49 1.03 2.58 19.98 52.17 0.13 - 0.66 - 1.95 1.55 0.23 0.18
M. fortuitum (7) 0.05 - 0.29 0.63 19.98 52.17 0.13 - 0.66 - 36.8 93.97 12.02 31.38
M. intracellulare (1) 0.54 - 0.54 - 0.27 - 0.13 - 0.66 - 1.37 - 0.16 -
M. kansasii (1) 0.21 - 0.05 - 0.27 - 0.13 - 0.66 - 1.37 - 0.32 -
M. mucogenicum (1) 0.86 - 27.6 - 138.3 - 0.53 - 2.06 - 43.75 - 1.3 -
M. parascrofulaceum (1) 1.72 - 0.05 - 138.3 - 0.13 - 0.66 - 1.37 - 0.16 -
M. phlei (3) 0.12 0.08 0.12 0.08 49.07 77.38 0.77 1.11 0.66 - 59.24 100.24 27.84 47.94
M. scrofulaceum (1) 0.21 - 0.05 - 0.27 - 0.13 - 0.66 - 1.37 - 0.32 -
M. simiae (4) 0.47 0.83 0.92 1.68 69.28 79.69 4.26 8.16 0.66 - 1.37 - 0.16 -
M. smegmatis (3) 0.11 0.093 0.54 - 46.28 79.69 0.13 - 0.66 - 30.07 49.72 7.04 11.91
M. terrae (7) 1.81 2.57 1.87 2.54 20.37 52.01 0.26 0.33 0.6 0.14 1.37 - 12.02 31.38
M. xenopi (2) 0.05 - 0.05 - 0.27 - 0.13 - 0.66 - 1.37 - 0.16 -
STR: Streptomycin, RIF: Rifampicin, ETH: Ethambutol, CIP: Ciprofloxacin, OFL: Ofloxacin, ATH: Azithromycin, CLA: Clarithromycin, M: Mean, SD: 
Standard deviation.Annals of Clinical Microbiology and Antimicrobials 2008, 7:15 http://www.ann-clinmicrob.com/content/7/1/15
Page 3 of 9
(page number not for citation purposes)
ter (Millipore®, Ireland). Tetrazolium bromide [3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide] (Sigma®, USA.) was prepared at a concentration of
1 mg/ml in absolute ethanol and 1.5 ml of 10% Tween 80
and the stock was stored in dark at 4°C. The mycobacte-
rial inoculum was prepared from log-phase culture of the
NTMs on LJ slants and their turbidity was adjusted to
McFarland Standard No. 1.
Tetrazolium Microplate Assay
TEMA was performed as previously described [13] with
minor modifications (Illustrated in Fig. 1). Briefly, 100 μL
of Middlebrook 7H9 broth (pH 7.2; Sigma®, USA) was
added to columns 2 to 11 in rows A to G (labeled on
microtitre plates). One-hundred-microliters of 2× concen-
tration of drug were added to columns 1 and 2. The anti-
biotics were serially diluted twofold in consecutive
columns by transferring 100 μL, except for column 10,
where 100 μL of excess medium was discarded. The final
drug concentrations in the wells were set as follows: STR:
27.6 to 0.0539 μg/mL, RIF: 27.6 to 0.0539 μg/mL, ETH:
138.3 to 0.27 μg/mL, CIP: 66 to 0.132 μg/mL, OFL: 33 to
0.66 μg/mL, ATH: 500 to 1.367 μg/mL and CLA 83.2 to
0.162 μg/mL. Hundred microliters of mycobacterial sus-
pension (set to McFarland Standard No.1) was added to
wells in rows A to G in columns 1 to 11. The wells in col-
umn 11 served as inoculum-growth control with no
drugs. The plates were incubated at 37°C for 5 days. On
day 5, 50 μl of the tetrazolium dye was added to well A11
and the plate was then incubated at 37°C for 24 h. A
change in colour from yellow to purple indicated growth
of bacteria and the MICs was interpreted visually.
Agar Proportion method
APM method was performed on Middlebrook 7H10 agar
plates as previously described by others [15,17]. The drug
concentrations in the agar plates were STR 8 μg/mL, RIF 2
μg/mL, ETH 40 μg/mL, CIP 2 μg/mL, OFL 2 μg/mL, ATH
200 μg/mL, and CLA 80 μg/mL. The strains were classified
as susceptible to a drug if the number of colonies was <1%
and resistant if the number of colonies was >10% in the
drug containing media to the number of colonies on the
control plate without any drug.
Data analysis
Analysis of data obtained by TEMA and the APM was car-
ried by SPSS® software (version 11.5). Receiver Operating
Characteristic (ROC) curve analysis was performed to
measure the Area Under Curve (AUC).
Results
The sensitivity and resistance patterns against STR, RIF,
ETH, CIP, OFL, ATH and CLA by both TEMA and APM are
described in Table 1. All the standard strains of NTMs
were sensitive to all the tested drugs. The mean MICs val-
ues of the drugs (Table 2) tested by TEMA varied between
Diagrammatic illustration of tetrazolium microplate assay Figure 1
Diagrammatic illustration of tetrazolium microplate assay.
Fig 1:  Diagrammatic illustration of Tetrazolium Microplate Assay
A
B
C
D
E
F
G
H
12 3456789 1 0 1 11 2
STR
RIF
ETH
CIP
OFL
ATH
CLA
100μl
STR: Streptomycin, RIF: Rifampicin, ETH: Ethambutol, CIP: Ciprofloxacin, OFL: Ofloxacin, ATH: Azithromycin, 
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clinical isolates belonging to different species. Of the 55
isolates, 23 (41.8%) were sensitive to all the drugs and the
remaining 32 (58.2%) were resistant to at least one drug
(Fig. 2).
When the efficiency of TEMA and APM were compared for
detecting susceptibility patterns in NTM isolates, they
showed 96.4% concordance for STR (Fig. 3), 98% con-
cordance for RIF (Fig. 4), 100% for ETH (Fig. 5), and CIP
(Fig. 6), and 98% for OFL (Fig. 7), ATH (Fig. 8) and CLA
(Fig. 9). The Area Under Curve (AUC) by ROC curve anal-
ysis for STR was 0.943, RIF was 0.950, ETH was 1.000, CIP
was 1.000, OFL was 0.750, ATH was 0.958 and CLA was
0.950. NTM isolates showed 90.09% and 98.18% of sus-
ceptibility to Ciprofloxacin and Ofloxacin, respectively.
TEMA was rapid and susceptibility results could be 
Drug resistance patterns of NTM Figure 2
Drug resistance patterns of NTM.
23
12
9
7
2
1
1
0 5 10 15 20 25
Sensitive to all drugs 
Single drug resistant 
Two drug resistant 
Three drug resistant 
Four drug resistant 
Five drug resistant 
Six drug resistant 
Number of Isolates
Fig 2: Drug resistance patterns of NTM
Table 2: Comparison of TEMA and APM for antimycobacterial susceptibility testing of Non-tubercular mycobacterial isolates
APM
STR RIF ETH CIP OFL ATH CLA
T E M A S R SRSR S R S R S R SR
Sensitive 4 3 14 5 0 3 6 05 0 0 5 30 4 3 04 5 0
Resistant 11 0 1 9 0 1 9 05 1 1 11 1 1 9
Total 44 11 46 9 36 19 50 5 54 1 44 11 46 9
Percentage (80%) (20%) (83.6%) (16.4%) (65.5%) (34.5%) (91%) (9%) (98.2%) (1.8%) (80%) (20%) (83.6%) (16.4%)
Concordance 96.4% 98% 100% 100% 98% 98% 98%
TEMA: Tetrazolium Microplate Assay, STR: Streptomycin, RIF: Rifampicin, ETH: Ethambutol, CIP: Ciprofloxacin, OFL: Ofloxacin, ATH: 
Azithromycin, CLA: Clarithromycin, S: Sensitive, R: Resistant.Annals of Clinical Microbiology and Antimicrobials 2008, 7:15 http://www.ann-clinmicrob.com/content/7/1/15
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Drug resistance patterns in individual species of NTM against Rifampicin Figure 4
Drug resistance patterns in individual species of NTM against Rifampicin.
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Drug resistance patterns in individual species of NTM against Streptomycin Figure 3
Drug resistance patterns in individual species of NTM against Streptomycin.
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Drug resistance patterns in individual species of NTM against Ethambutol Figure 5
Drug resistance patterns in individual species of NTM against Ethambutol.
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Drug resistance patterns in individual species of NTM against Ciprofloxacin Figure 6
Drug resistance patterns in individual species of NTM against Ciprofloxacin.
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Drug resistance patterns in individual species of NTM against Ofloxacin Figure 7
Drug resistance patterns in individual species of NTM against Ofloxacin.
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Drug resistance patterns in individual species of NTM against Azithromycin Figure 8
Drug resistance patterns in individual species of NTM against Azithromycin.
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obtained in a median time period of 5 to 9 days as com-
pared to 12 to 25 days by APM.
Discussion
The epidemiology of mycobacterial infections had
changed drastically in the past few decades and in-turn
changing the treatment regimen and management prac-
tices, especially after AIDS epidemic [18]. In the terminal
stages of AIDS, where CD4
+ lymphocyte counts falls below
100, not only M. tuberculosis but several NTM also cause
infection and can be isolated from blood, tissue, sputum
and fecal samples [19]. The NTM disease not necessarily
remains localized, but cause disseminated infection such
as M. avium-intracellulare complex (MAC) [20]. The prog-
nosis for the MAC infected AIDS patient is usually poor,
largely due to the inherent resistance of these organisms to
most of the available anti-tubercular drugs and have high
toxicity.
Seventeen (30.9%) of the 55 NTM isolates studied here
were isolated from patients who were earlier treated with
anti-tuberculosis therapy (ATT) without any clinical
improvement. In clinical settings, these non-responsive
cases are later labeled as Multi-drug resistant tuberculosis
(MDR) by missing NTM infections. Similar observations
were reported with other studies carried out in other
countries such as Iran [21] and Brazil [22]. The clinical
and radiological features of NTM infected patients like
abnormal chest roentgenograms with infiltrations, nodu-
lar abscesses, cavities, lymphoadenopathy resembling TB
can mislead the physician.
TEMA was effectively used to detect drug resistance in
NTM isolates and was compared with the APM to which it
had very good concordance (table 2). Previously similar
results were obtained with M. tuberculosis (Data not pub-
lished), prompted us to evaluate with other mycobacterial
species. In this regard, the TEMA results were accurate,
highly reproducible and rapid to determine the MICs of
clinically significant mycobacteria.
However, before applying the TEMA as a routine drug sus-
ceptibility testing method, a multicentric and inter labora-
tory testing must be carried out with a supervision of
international agencies such as World Health Organisation
to validate our findings and to implement it in resource
poor settings. We recommend that the TEMA, which is a
calorimetric method, is more appropriate for level 3 refer-
ence laboratories to manipulate small volume of liquid
cultures in a microplate format.
Drug resistance patterns in individual species of NTM against Clarithromycin Figure 9
Drug resistance patterns in individual species of NTM against Clarithromycin.
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